Drug intelligence / Profile preview

SPC 2004

Development stage: Unknown
Lead developer: Shinpoong Pharma
Modality: Small Molecules
Administration: Oral

Overview

**SPC 2004** is a Shin Poong Pharmaceutical investigational dual-component antihypertensive treatment evaluated as an active comparator in the SPC1001 development program for **essential hypertension**. In the Phase 2b SPC1001 study, it was one of the dual-component regimens used to assess the contribution of individual agents within the candesartan, amlodipine, and indapamide triple-combination program. Publicly available trial materials identify SPC 2004 as a dual-component comparator but do not clearly assign its precise two-active composition; it should therefore not be conflated with the unrelated Santaris antisense oncology compound also reported historically as SPC-2004.

Other names: Anti-Bcl-2 (LNA antisense therapy)Santaris

Targets

Apoptosis regulator Bcl-2 mRNA

Beyond the preview

Go deeper on SPC 2004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPC 2004.

Explore the full profile